Armen  Shanafelt net worth and biography

Armen Shanafelt Biography and Net Worth

Dr. Armen B. Shanafelt Ph.D. serves as Independent Director of the Company. Dr. Shanafelt has served as venture partner, then general partner, of Lilly Ventures, a venture capital firm. Prior to joining Lilly Ventures, Dr. Shanafelt was one of several Chief Science Officers at Eli Lilly and Company, a pharmaceutical research company, specifically responsible for the generation of the early biotherapeutic pipeline which spanned the therapeutic areas of oncology, endocrine and neuroscience. Dr. Shanafelt also serves on the board of directors of Surface Oncology, Inc. Dr. Shanafelt previously served on the boards of directors of Aileron Therapeutics, Inc., Protagonist Therapeutics, Inc., Sutro Biopharma, Inc., and Symic Bio. Dr. Shanafelt received his B.S. in Chemistry and Physics from Pacific Lutheran University and his Ph.D. in Chemistry from the University of California, Berkeley. He completed his postdoctoral work at DNAX Research Institute. He is a Kauffman Fellow (Class 14). Shanafelt is qualified to serve on our board of directors because of his experience in the pharmaceutical and biotechnology businesses, including his expertise with respect to the generation of early biotherapeutic pipelines and his investment and board experience while a partner with Lilly Ventures.

How do I contact Armen Shanafelt?

The corporate mailing address for Dr. Shanafelt and other Aeglea BioTherapeutics executives is 805 LAS CIMAS PARKWAY SUITE 100, AUSTIN TX, 78746. Aeglea BioTherapeutics can also be reached via phone at (512) 942-2935 and via email at [email protected]. Learn More on Armen Shanafelt's contact information.

Has Armen Shanafelt been buying or selling shares of Aeglea BioTherapeutics?

Armen Shanafelt has not been actively trading shares of Aeglea BioTherapeutics during the last quarter. Most recently, on Monday, December 13th, Armen Shanafelt bought 587 shares of Aeglea BioTherapeutics stock. The stock was acquired at an average cost of $91.25 per share, with a total value of $53,563.75. Learn More on Armen Shanafelt's trading history.

Who are Aeglea BioTherapeutics' active insiders?

Aeglea BioTherapeutics' insider roster includes Jonathan Alspaugh (CFO), Anthony Quinn (CEO), and Armen Shanafelt (Director). Learn More on Aeglea BioTherapeutics' active insiders.

Armen Shanafelt Insider Trading History at Aeglea BioTherapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/13/2021Buy587$91.25$53,563.75View SEC Filing Icon  
12/9/2021Buy4,871$91.75$446,914.25View SEC Filing Icon  
See Full Table

Armen Shanafelt Buying and Selling Activity at Aeglea BioTherapeutics

This chart shows Armen Shanafelt's buying and selling at Aeglea BioTherapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Aeglea BioTherapeutics Company Overview

Aeglea BioTherapeutics logo
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $11.47
Low: $9.47
High: $13.76

2 Week Range

Now: N/A

Volume

43,300 shs

Average Volume

95,409 shs

Market Capitalization

$48.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.57